ORTHO-NOVUM 7/14-21
Clinical safety rating
cautionComprehensive clinical and safety monograph for ORTHO-NOVUM 7/14-21 (ORTHO-NOVUM 7/14-21).
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
| Metabolism | Ethinyl estradiol undergoes hepatic oxidation via CYP3A4 and conjugation; norethindrone primarily hepatic reduction and conjugation. |
| Excretion | Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor |
| Half-life | Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days |
| Protein binding | Norethindrone: 80-90% bound to SHBG and albumin; Ethinyl estradiol: 97-98% bound to albumin and SHBG |
| Volume of Distribution | Norethindrone: 2.5-4 L/kg; Ethinyl estradiol: 2.5-3 L/kg; clinical meaning: extensive tissue distribution |
| Bioavailability | Norethindrone: 64%; Ethinyl estradiol: 38-48% (oral, due to first-pass metabolism) |
| Onset of Action | Oral: suppression of ovulation begins after 7 consecutive days of use |
| Duration of Action | Oral: 24 hours (maintains contraceptive efficacy with daily dosing); note: missed pills reduce effectiveness |
| Molecular Weight | 312.45 |
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment necessary for mild to moderate renal impairment. Avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to potential fluid retention and hyperkalemia. |
| Liver impairment | Contraindicated in acute hepatic disease or Child-Pugh Class B and C cirrhosis. For Child-Pugh Class A, use with caution and monitor liver function; no specific dose adjustment guidelines available. |
| Pediatric use | Not indicated for use in children; contraindicated prior to menarche. |
| Geriatric use | Not indicated for use in postmenopausal women; avoid use in elderly due to increased risk of thrombotic and cardiovascular events. |
| 1st trimester | Contraindicated due to risk of oral clefts and cardiovascular defects from progestin exposure. |
| 2nd trimester | Contraindicated due to potential androgenic effects on female fetus. |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus and neonatal hepatotoxicity. |
Clinical note
Comprehensive clinical and safety monograph for ORTHO-NOVUM 7/14-21 (ORTHO-NOVUM 7/14-21).
| Placental transfer | High; both estrogen and progestin components cross the placenta readily and achieve fetal serum concentrations comparable to maternal levels. |
| Breastfeeding | Excreted in breast milk in small amounts; may reduce milk production and quality. Use alternative contraception unless benefit outweighs risk. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Combination hormonal contraceptives (estrogen-progestin) are contraindicated in pregnancy. First trimester exposure is associated with a low risk of congenital anomalies; however, second and third trimester exposure may increase risks of fetal genital tract abnormalities and possibly other adverse outcomes. Use is not recommended during any trimester. |
| Fetal Monitoring | If inadvertent use in early pregnancy occurs, no specific monitoring is required beyond routine prenatal care. Advise discontinuation if pregnancy is confirmed. |
| Fertility Effects | Ortho-Novum 7/14-21 is used for contraception and does not impair long-term fertility. Return to fertility typically occurs within a few months after discontinuation. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
| Serious Effects |
Known or suspected pregnancyHistory of thromboembolic disordersCerebrovascular or coronary artery diseaseBreast cancer or other estrogen-dependent neoplasiaUndiagnosed abnormal genital bleedingLiver tumors or active liver diseaseHypersensitivity to any component
| Precautions | Increased risk of thromboembolic disorders (stroke, MI, DVT/PE), Hepatic neoplasia risk, Elevated blood pressure, Gallbladder disease, Carbohydrate/lipid metabolism effects, Ocular lesions (retinal thrombosis), Depression, Drug interactions (e.g., rifampin, anticonvulsants) |
| Food/Dietary | Grapefruit juice may increase ethinyl estradiol concentrations; avoid excessive consumption. No other significant food interactions. |
| Clinical Pearls | For Ortho-Novum 7/14-21, a triphasic oral contraceptive containing norethindrone and ethinyl estradiol, counsel patients that missed pills require backup contraception; the risk of venous thromboembolism is highest in the first year of use and in smokers over 35; monitor blood pressure at baseline and follow-up; use with caution in patients with migraine with aura; GI disturbances (vomiting, diarrhea) may reduce efficacy. |
| Patient Advice | Take one tablet daily at the same time, starting on the first Sunday after your period begins. · If you miss a pill, refer to the package insert for specific instructions; use backup contraception as directed. · Common side effects include nausea, breast tenderness, and breakthrough bleeding; these often improve after 3 cycles. · Do not smoke while taking this medication, especially if you are over 35 years old, due to increased risk of blood clots. · Contact your healthcare provider immediately if you experience sudden chest pain, shortness of breath, leg pain or swelling, severe headache, or vision changes. |
Loading safety data…